Dupilimab

Alternative Names: Dupixent

Dupixent is a biologic medication used to treat moderate to severe eosinophilic or steroid-dependent asthma in patients aged 6 and older. It is a monoclonal antibody that blocks interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling, key drivers of type 2 (Th2) inflammation in asthma. Dupixent is given via subcutaneous injection, typically every other week, and can significantly reduce exacerbations, improve lung function, and lower the need for oral corticosteroids. It is not a rescue medication and is reserved for patients who remain uncontrolled despite high-dose inhaled corticosteroids and additional controller medications. Side effects may include injection site reactions, conjunctivitis, and eosinophilia.

 

Treatment Type: Prescription Medication

Treatment Class: IL-4 antagonist

Treatment Modality: Injection

Dupilimab
Dupilimab
Dupilimab

Review Summary

4.0

1 Reviews

Preferred by 1 Reviewers

Based on the review, Dupilumab appears to be an effective biologic treatment for moderate to severe asthma, particularly for patients with eosinophilic asthma or those dependent on oral steroids. The treatment helps reduce asthma exacerbations and the need for systemic steroids in patients who are not well-controlled by standard inhaler therapy.

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
3.0
1 = Very Expensive 5 = Very Affordable

3.0

Moderate Cost
Relief Speed
2.0
1 = No Relief 5 = Immediate Relief

2.0

Slow Relief
Side Effects
4.0
1 = Intolerable Effect 5 = No Effect

4.0

Mild Effect
Treatment Line
1.0
1 = Third-line or more 5 = First-line

1.0

Third-line or more

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

4.0

1 Reviews
5
0%
4
100%
3
0%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the review, Dupilumab appears to be an effective biologic treatment for moderate to severe asthma, particularly for patients with eosinophilic asthma or those dependent on oral steroids. The treatment helps reduce asthma exacerbations and the need for systemic steroids in patients who are not well-controlled by standard inhaler therapy.

Reviews

Filter by reviewer type Pro

Select all Clear all

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
3 months ago
Dupilimab is an effective add-on biologic therapy for patients with moderate to severe asthma, particularly those with an eosinophilic phenotype or oral steroid dependence. It reduces exacerbation frequency and the need for systemic steroids in patients who remain poorly controlled on standard inhaler therapy, with added value when other Dupilimab-approved indications are also present.
Review Image
#ModerateCost #CoveredByInsurance #SlowRelief #MildEffect #Third-lineOrMore #Maintenance
View Professional Disclosures

Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.

We use cookies to personalize our services and provide you with the best possible experience. By continuing to use this site, you agree to this cookie usage. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can learn more about cookies and how your data is processed in the Privacy Policy.

Strictly Necessary Only Accept All